Editas Medicine, Inc.: Form 10-Q for the period ended Jun 30, 2022
Filed with the SEC on Aug 3, 2022 and accepted by EDGAR at Aug 3, 2022, 16:31 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-04-01 to 2022-06-30 | $6.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2022-01-01 to 2022-06-30 | $13.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2022-04-01 to 2022-06-30 | $43.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2022-01-01 to 2022-06-30 | $81.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-04-01 to 2022-06-30 | −$54.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-01-01 to 2022-06-30 | −$105.0m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2022-04-01 to 2022-06-30 | −$53.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2022-01-01 to 2022-06-30 | −$104.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-04-01 to 2022-06-30 | −$0.78 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2022-01-01 to 2022-06-30 | −$1.52 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-04-01 to 2022-06-30 | −$0.78 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-01-01 to 2022-06-30 | −$1.52 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-04-01 to 2022-06-30 | 68,640,858 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2022-01-01 to 2022-06-30 | 68,563,348 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2022-01-01 to 2022-06-30 | −$87.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2022-01-01 to 2022-06-30 | $2.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-06-30 | $169.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-06-30 | $461.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-06-30 | $580.8m | us-gaap:Assets |
| Current liabilities | At period end2022-06-30 | $36.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-06-30 | $115.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-06-30 | $465.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-22-011904. Last ingested by Listed: Oct 27, 2026, 17:28 ET. Listed shows no prices and gives no investment advice.